$1.19
5.04%
Downside
Day's Volatility :11.9%
Upside
7.22%
55.46%
Downside
52 Weeks Volatility :94.98%
Upside
88.73%
Period | Bone Biologics Corp | Index (Russel 2000) |
---|---|---|
3 Months | -22.73% | 0.0% |
6 Months | -49.15% | 0.0% |
1 Year | -78.72% | 0.0% |
3 Years | -99.9% | -22.3% |
Market Capitalization | 2.2M |
Book Value | $2.21 |
Earnings Per Share (EPS) | -17.24 |
PEG Ratio | 0.0 |
Wall Street Target Price | 16.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -57.25% |
Return On Equity TTM | -119.03% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -825.0K |
Diluted Eps TTM | -17.24 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.17 |
EPS Estimate Next Year | -2.19 |
EPS Estimate Current Quarter | -1.39 |
EPS Estimate Next Quarter | -1.34 |
What analysts predicted
Upside of 1307.56%
Sell
Neutral
Buy
Bone Biologics Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bone Biologics Corp | -35.33% | -49.15% | -78.72% | -99.9% | -99.9% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bone Biologics Corp | 0.09 | NA | 0.0 | -3.17 | -1.19 | -0.57 | NA | 2.21 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bone Biologics Corp | Buy | $2.2M | -99.9% | 0.09 | 0.0% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Bone Biologics Corp
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 130.1%
Tower Research Capital LLC
UBS Group AG
McMahon Financial Advisors, LLC
a publicly-held biotechnology company that is a spin off of the musculoskeletal transplant foundation (mtf) using technology discovered and licensed from ucla. bone biologics market and focus is in the regenerative medicine orthobiologics space. bone biologics was founded in 2004 by university of california professors in collaboration with an osaka university professor and a usc surgeon and acquired in 2006 by mtf as the major shareholder, who has been the primary funder since the acquisition. the company’s proprietary, patented platform technology ucb-1™, exclusively licensed from ucla, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and rhesus monkey) studies that have demonstrated that the ucb-1™ technology facilitates superior normal bone growth. the company believes that as a platform technology, ucb-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.
Organization | Bone Biologics Corp |
Employees | 2 |
CEO | Mr. Jeffrey Frelick |
Industry | Biotechnology |
A Spac I Acquisition Corp
$1.19
-4.03%
Keyarch Acquisition Corp
$1.19
-4.03%
Connexa Sports Technologies Inc
$1.19
-4.03%
Us Value Etf
$1.19
-4.03%
First Wave Biopharma Inc
$1.19
-4.03%
Global X Msci Next Emerging
$1.19
-4.03%
Fat Projects Acquisition Corp
$1.19
-4.03%
Capital Link Global Fintech
$1.19
-4.03%
Applied Uv Inc
$1.19
-4.03%